Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

NCT07109765 · tracked via the Priya Life Science China tracker

Sponsor

Peking Union Medical College

Phase

Observational

Started

2025-06-01

Last updated

2025-08-07

Condition(s) studied

Hidradenitis Suppurativa (HS)

Investigational drug(s) / intervention(s)

Secukinumab →

Secukinumab: secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection

Study summary

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * age ≥18 years * diagnosis of moderate-to-severe HS with Hurley stage II or III * Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules * inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors Exclusion Criteria: * active infections (e.g., viral hepatitis, active tuberculosis) * use of other biologics or systemic immunosuppressants within the past three months * severe organ dysfunction (e.g., hepatic or renal failure) * any other conditions that might affect study results

Primary outcome measure(s)

Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) — From enrollment to the end of treatment at Week 12
a ≥50% reduction in the combined count of inflammatory nodules and abscesses from baseline, without an increase in the number of abscesses or draining tunnels

Trial sites (1)

Facility	City	Region	Status
No. 1 Shuai Fu Yuan, Dongcheng District, Beijing	Beijing	Beijing Municipality	Recruiting

On this site

📄 Cosentyx (secukinumab) drug profile →

More Peking Union Medical College trials in China

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC Recruiting

Critical Closing Pressure and PCO₂ Gap in Fluid Resuscitation for Septic Shock Active, not recruiting

Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning Recruiting

Tooth and Bone-borne Cutting/Repositioning Guide and Patient-specific Implant(PSI) Recruiting

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing Recruiting

Other trials for the same condition

A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa Starting soon

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa Recruiting

Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS Starting soon

A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients Recruiting

Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using fMRI Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07109765 on ClinicalTrials.gov ↗ ← All trials in China